ClinicalTrials.gg
RecruitingNCT07072039PEACEUpdated Oct 6, 2026

Evaluation of the Paramedic Evaluation for Acute COPD Exacerbation

An interventional study of Paramedic Evaluation for acute COPD Exacerbation and Usual Care in COPD (Chronic Obstructive Pulmonary Disease), sponsored by University of Massachusetts, Worcester. Recruiting at 1 site in United States. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-10-06.

Sponsored by University of Massachusetts, Worcester · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year 1 month later.
Updated Oct 6, 2026Study documents postedEnrollment updated+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
75
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,280 studies in Pulmonary Disease, Chronic Obstructive with a site in United States — 139 open to participants now, 174 under way, 21 of them phase 3. Pulmonary Disease, Chronic Obstructive · United States.

Planned enrollment
563rd of 1,039
75 · median 100
Started
2025
with 44 others
No phase
395 of 1,280
52 open now
Primary completion
2029-07
later than 143 of 173 live
Registered
1,216th of 1,280
by date

Among the 1,280 studies in Pulmonary Disease, Chronic Obstructive with a site in United States, this one is the 563rd largest by planned enrollment of the 1,039 interventional ones that give a count, is one of 45 that started in 2025, is one of 395 with no phase, reaches primary completion later than 143 of the 173 other live ones, and was the 1,216th registered.

Pulmonary Disease, Chronic Obstructive

5,528 studies on the registry are indexed under Pulmonary Disease, Chronic Obstructive; 858 are open to participants now.

Browse Pulmonary Disease, Chronic Obstructive studies →

Open to participants now

139 of the 1,280 studies in Pulmonary Disease, Chronic Obstructive with a site in United States are open now. Recruiting first, the newest first:

134 more — sign in →

All 139 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 560 Pulmonary Disease, Chronic Obstructive studies recruiting now, 307 (55%) set no upper age limit and 82 (15%) stop at 75 or younger; 30 take children under 18; 88 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,280 studies in Pulmonary Disease, Chronic Obstructive with a site in United States, or all of them as a file.
02

Study summary

Chronic Obstructive Pulmonary Disease (COPD) is a serious lung condition that affects millions of people in the United States. Each year, it leads to about 150,000 deaths, nearly 900,000 emergency room visits, and 700,000 hospital stays. When COPD symptoms suddenly get worse-called an exacerbation-it can seriously harm a person's quality of life and often requires emergency care. Treating these flare-ups early can help prevent hospital visits, but right now, there aren't many good ways to make sure people get care quickly.

Mobile Integrated Health (MIH) programs send specially trained paramedics, guided remotely by doctors, to care for patients in their homes. This approach could help people with COPD get faster, more effective care without needing to go to the hospital.

In this project, the investigators are testing a new program called PEACE (Paramedic Evaluation for Acute COPD Exacerbation). The PEACE program sends community paramedics to patients' homes-when needed and in partnership with their regular doctors-to manage worsening COPD symptoms early. The study team will adapt the PEACE program to meet the needs of adults living at home with moderate to severe COPD, gather feedback from patients and healthcare providers, and run a small pilot study to see if the program is practical and helpful.

Read the detailed description

Evidence-based strategies to ensure that patients with COPD have reliable, timely, equitable access to treatment are lacking. This deficit is particularly evident in communities impacted by determinants of health that adversely impact preventive health behavior and care access.

On-demand Mobile Integrated Health (MIH) teams, comprised of community paramedics supported by centralized physicians, have been developed to care for patients outside of conventional hospital settings. These teams empower physicians to provide enhanced remote care by collecting essential clinical information about patients in their living environment, performing diagnostic testing, and administering therapy in the home. MIH programs decrease emergency medical services utilization and improve patient satisfaction in select populations, but the impact of MIH programs on the outcomes of patients with COPD exacerbation has not been evaluated.

In this project, the study team will implement and refine an MIH intervention for patients living with COPD. The Paramedic Evaluation for Acute COPD Exacerbation (PEACE) intervention will dispatch community paramedics to execute a home-based evaluation and treatment strategy in collaboration with a supervising physician and the patient's ambulatory medical team during and after acute COPD exacerbation to promote wellness and recovery. This intervention is intended to improve clinical outcomes and reduce acute care costs by eliminating barriers to care, generating actionable clinical data that can facilitate appropriate diagnosis, accelerating treatment, and simplifying care coordination. Our central hypothesis, based on preliminary data and input from key informants, is that an intervention that facilitates community-based management of COPD exacerbation will be acceptable and highly adoptable by patients and clinicians.

The Practical Robust Implementation and Sustainability Model (PRISM) implementation framework will be used to describe factors impacting project implementation, with the embedded Expanded RE-AIM (Reach, Effectiveness, Adoption, Implementation, Maintenance) model guiding outcomes measurements. Leveraging our prototypical intervention design, the study team will test and Refine the prototype PEACE intervention in real clinical practice with a cohort of patients who are at high risk of COPD exacerbation. The study team will use a mixed-methods approach to evaluate the usability and acceptability of each operational and clinical component of PEACE. Measures will include a systematic assessment of protocol adherence, survey instruments, and qualitative interviews to explore contextual factors impacting intervention performance. The study team will confirm our findings and adapt the protocols informed by a working group comprised of clinicians and community partners. Up to 25 patient participants will be enrolled in the intervention, plus up to 11 clinician participants will be enrolled to participate in usability/acceptability ratings and qualitative evaluations/focus groups.

03

Conditions studied

  • COPD (Chronic Obstructive Pulmonary Disease)

Keywords

  • Community Paramedicine
  • Mobile Integrated Health
  • COPD (Chronic Obstructive Pulmonary Disease)
04

Who can participate

The criteria were revised on the registry on Oct 2, 2026. See what changed

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

1) Diagnosis of 4) Receives care in the UMass Memorial Medical Center System 5) 40 years of age or older 6) Speaks English 7) Resides in the geographical catchment area allowed by the UMass Memorial Medical Center MIH Program's license

Exclusion criteria

Exclusion Criteria:

  1. No prior diagnosis of
  2. Pregnancy
  3. Cannot provide
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
75 participants (estimated)

Study arms

  • Experimental
    PEACE Arm

    Patients in this arm will receive PEACE Intervention

    Procedure: Paramedic Evaluation for acute COPD Exacerbation

  • Placebo comparator
    Control Arm

    control arm participants will receive usual care

    Procedure: Usual Care

Interventions

  • ProcedureParamedic Evaluation for acute COPD Exacerbation

    The Paramedic Evaluation for Acute COPD Exacerbation (PEACE) program is a mobile integrated health initiative that aims to evaluate and treat COPD exacerbation in the home. The goal of the intervention is to expedite the recognition and treatment of COPD exacerbation as well as For this intervention, ambulatory teams can refer patients for PEACE visits when a patient has been identified as suffering from symptoms consistent with COPD exacerbation. Once a visit is requested via electronic health record order, a community paramedic presents to the patient's home within 2 hours, evaluates the patient using mobile diagnostic testing, and initiates pharmacological therapies protocolized by the pulmonary team. A standardized clinical approach and documentation strategy is used including a focused history and physical exam, venous blood gas, trending pulse-oximetry, and mobile x-ray. The community paramedic is supervised in real-time by an emergency physician to establish a care plan and di

  • ProcedureUsual Care

    Patients will receive care as usual. They will be asked to complete survey instruments as part of their participation in the study

06

What researchers measure

Primary outcomes

  1. Recruitment Rate

    Ratio of patients enrolled to total patients approached

    Time frame: At enrollment

  2. Reason for Recruitment Refusal

    Reason that approached patients did not enroll in the study

    Time frame: At enrollment

  3. Intervention Acceptability

    Using the healthcare intervention acceptability qualitative framework, investigators will measure intervention acceptability from both patient and clinician perspectives. This validated framework assesses participants' affective attitudes, sense of intervention coherence, self-efficacy, the perceived ethicality of the intervention, intervention burden and anticipated cost, opportunity cost, and perceived effectiveness.

    Time frame: from enrollment until completion of study activities at 1 year

  4. Protocol Fidelity

    Investigators will evaluate adherence to each component of the PEACE protocol by having two independent physician-reviewers audit the EHR and video recordings from every PEACE encounter to ensure that procedures were completed correctly and within the expected timeframe. Particular attention will be focused on visits with operational or clinical "failures," defined as any clinical or operational deviation from intervention protocol or any unexpected ED visit or hospitalization within 72 hours of a PEACE referral.

    Time frame: From enrollment until study completion at 1 year

  5. Sample Retention

    Investigators will track the number of subjects who completed the entire study compared to the number of subjects initially enrolled. The investigators will also evaluate loss to follow-up rate, perceived reason for discontinuation and completeness of post-intervention data collection.

    Time frame: From enrollment until completion of study activities at 1 year

  6. PEACE Referrals

    Investigators will track the total number of PEACE referrals requested during the study period

    Time frame: 6 and 12 months after enrollment

Secondary outcomes

  1. PEACE Disposition

    Distribution of participant clinical disposition after PEACE encounter (home versus emergency department)

    Time frame: 6 and 12 months after enrollment

  2. Unanticipated ED Visits

    ED visits within 72 hours after PEACE visit where patient was treated in place

    Time frame: From enrollment to completion of study activities at 1 year

  3. Hospitalizations

    Number and length of hospitalizations for COPD

    Time frame: From enrollment until completion of study activities at 1 year

  4. Exacerbation Relapse Rate

    Number of occurrences when patients experience worsening COPD symptoms requiring a second pharmacological intervention before resolution of symptoms from a treated exacerbation

    Time frame: From enrollment until completion of study activities at 1 year

  5. COPD-related Medication changes

    Number of adjustments made to study participants' COPD treatment regimen (initiation, discontinuation, dosage adjustment, or substitution of medications aimed at managing COPD)

    Time frame: From enrollment to completion of study activities at 1 year

07

Study locations

1 of 1 sites recruiting
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — Clinical and laboratory data: Includes medical history, demographic information, and patient characteristics at enrollment. Other data will be extracted from the electronic health record and patient-facing instruments at 3, 6, and 12 months. This includes healthcare utilization patterns, instances of COPD exacerbation relapse, COPD-related medication adjustments, and mortality. Additionally, patient-reported COPD-related quality-of-life instruments will be captured and tracked throughout the study. These values will be reported as tabular data and stored in a REDCap secure electronic data capture system. Interview data: Semi-structured interviews will be performed with patients, clinicians, and administrators. Deidentified, raw transcripts will be generated and coded using methods described in the research strategy. Codebooks will be developed and used for coding transcripts. Codebooks and coding summary files will be shared as detailed below.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report, Analytic code

Time frame: Baseline data (data collected before any intervention), such as demographics, that require no additional analyses, will be submitted within 4 months after enrollment is completed. After the study is complete, the study team will submit all remaining scientific data to the data repository and will mark the RCT status as "complete" in clinicaltrials.gov. Under the current repository policies, data will be preserved and available for the wider research community in perpetuity.

Access criteria: Prior to the release of individual-level data, researchers will be required to complete data sharing and confidentiality agreements as established by the data repository. Researchers must commit to 1) not attempting to re-identify participants, 2) securing the data with appropriate technology and enforcing strict access rules, 3) destroying data after analyses are completed, 4) meeting any requirements as stipulated by the health system involved in the study, and 5) if research is conducted within a covered entity, HIPAA requirements must be met prior to use.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Jul 2029, 45 months after the start.

Of 1,099 non-industry interventional studies with no phase under Pulmonary Disease, Chronic Obstructive, half reached primary completion within 22 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 45 months is above that.

Counting every sponsor, half of 1,187 studies reached it within 22 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 26, 2025
First posted
Jul 18, 2025
StartActual
Oct 1, 2025
Primary completionEst.
Jul 1, 2029
CompletionEst.
Sep 1, 2029
Last update
Oct 6, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Enrollment
50→75
Oct 2, 2026
Eligibility
Minimum age 18 Years→40 Years; 1 inclusion criterion edited, 6 removed; 2 exclusion criteria removed
What changed in the criteria
Inclusion criteria
  • RemovedDiagnosis of COPD
  • RemovedAt least one COPD exacerbation resulting in ED utilization in the six months prior to enrollment
  • RemovedCOPD GOLD Score letter designation of B, C, or D
  • RemovedReceives care in the UMass Memorial Medical Center Pulmonary Clinic or Benedict Family Health Clinic
  • RemovedOver 18 years of age
  • RemovedSpeaks English
  • Edited1) Diagnosis of COPD 4) Receives care in the UMass Memorial Medical Center System 5) 40 years of age or older 6) Speaks English 7) Resides in the geographical catchment area allowed by the UMass Memorial Medical Center MIH Program's license
Exclusion criteria
  • RemovedUnder 18 years of age
  • RemovedDoes not speak English
Oct 2, 2026
Interventions
Added Procedure: Usual Care. Arms added: Control Arm
Oct 2, 2026
Documents
across 2 updates, Oct 2, 2026 – Oct 6, 2026
Show all 2 updates
  1. Oct 6, 2026
    Documents Study protocol ↗ updated · Informed consent form ↗ updated
    + 1 other change: verification date
  2. Oct 2, 2026
    Enrollment 50→75
    Eligibility Minimum age 18 Years→40 Years; 1 inclusion criterion edited, 6 removed; 2 exclusion criteria removed
    What changed in the criteria
    Inclusion criteria
    • RemovedDiagnosis of COPD
    • RemovedAt least one COPD exacerbation resulting in ED utilization in the six months prior to enrollment
    • RemovedCOPD GOLD Score letter designation of B, C, or D
    • RemovedReceives care in the UMass Memorial Medical Center Pulmonary Clinic or Benedict Family Health Clinic
    • RemovedOver 18 years of age
    • RemovedSpeaks English
    • Edited1) Diagnosis of COPD 4) Receives care in the UMass Memorial Medical Center System 5) 40 years of age or older 6) Speaks English 7) Resides in the geographical catchment area allowed by the UMass Memorial Medical Center MIH Program's license
    Exclusion criteria
    • RemovedUnder 18 years of age
    • RemovedDoes not speak English
    Interventions Added Procedure: Usual Care. Arms added: Control Arm
    + 2 other changes: verification date and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07072039
Responsible party
Laurel O'Connor (Associate Professor of Emergency Medicine, University of Massachusetts, Worcester) — Principal investigator
First posted
Jul 18, 2025
Start date
Oct 1, 2025
Primary completion
Jul 1, 2029 (estimated)
Completion
Sep 1, 2029 (estimated)
Last update
Oct 6, 2026

Study contacts

Laurel O'Connor, MD, MSc
Contact
laurel.oconnor@umassmed.edu
508-421-1400
Laurel O'Connor, MD, MSc
principal investigator · University of Massachusetts, Worcester

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion